GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » ROC (Joel Greenblatt) %

HighTide Therapeutics (HKSE:02511) ROC (Joel Greenblatt) % : -7,765.87% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. HighTide Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -7,765.87%.

The historical rank and industry rank for HighTide Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

HKSE:02511' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11284.32   Med: -6276.59   Max: -4419.33
Current: -11284.32

During the past 3 years, HighTide Therapeutics's highest ROC (Joel Greenblatt) % was -4419.33%. The lowest was -11284.32%. And the median was -6276.59%.

HKSE:02511's ROC (Joel Greenblatt) % is ranked worse than
92.9% of 1465 companies
in the Biotechnology industry
Industry Median: -333.95 vs HKSE:02511: -11284.32

HighTide Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


HighTide Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for HighTide Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics ROC (Joel Greenblatt) % Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-6,276.59 -4,419.33 -9,441.20

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
ROC (Joel Greenblatt) % - -4,100.90 -4,822.69 -22,028.62 -7,765.87

Competitive Comparison of HighTide Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, HighTide Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HighTide Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's ROC (Joel Greenblatt) % falls into.



HighTide Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 21.694) - (42.49 + 0 + 287.002)
=-307.798

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 39.046) - (46.166 + 0 + 34.602)
=-41.722

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of HighTide Therapeutics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-851.644/( ( (5.547 + max(-307.798, 0)) + (16.386 + max(-41.722, 0)) )/ 2 )
=-851.644/( ( 5.547 + 16.386 )/ 2 )
=-851.644/10.9665
=-7,765.87 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HighTide Therapeutics  (HKSE:02511) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


HighTide Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


HighTide Therapeutics (HKSE:02511) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines